Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Celldex Therapeutics (CLDX) Retained Earnings (2016 - 2025)

Historic Retained Earnings for Celldex Therapeutics (CLDX) over the last 16 years, with Q3 2025 value amounting to -$1.7 billion.

  • Celldex Therapeutics' Retained Earnings fell 1488.81% to -$1.7 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.7 billion, marking a year-over-year decrease of 1488.81%. This contributed to the annual value of -$1.6 billion for FY2024, which is 1129.72% down from last year.
  • Latest data reveals that Celldex Therapeutics reported Retained Earnings of -$1.7 billion as of Q3 2025, which was down 1488.81% from -$1.7 billion recorded in Q2 2025.
  • Over the past 5 years, Celldex Therapeutics' Retained Earnings peaked at -$1.1 billion during Q1 2021, and registered a low of -$1.7 billion during Q3 2025.
  • Moreover, its 5-year median value for Retained Earnings was -$1.3 billion (2023), whereas its average is -$1.3 billion.
  • As far as peak fluctuations go, Celldex Therapeutics' Retained Earnings tumbled by 620.83% in 2021, and later tumbled by 1488.81% in 2025.
  • Over the past 5 years, Celldex Therapeutics' Retained Earnings (Quarter) stood at -$1.1 billion in 2021, then decreased by 9.82% to -$1.3 billion in 2022, then fell by 11.26% to -$1.4 billion in 2023, then dropped by 11.3% to -$1.6 billion in 2024, then dropped by 11.41% to -$1.7 billion in 2025.
  • Its last three reported values are -$1.7 billion in Q3 2025, -$1.7 billion for Q2 2025, and -$1.6 billion during Q1 2025.